125 related articles for article (PubMed ID: 30488197)
1. Tumor-Infiltrating Lymphocytes in Breast Cancer. Association with Clinical and Pathological Parameters.
Zabotina TN; Korotkova OV; Chertkova AI; Zakharova EN; Tabakov DV; Dzhgamadze NT; Savostikova MV; Artamonova EV; Khailenko VA; Kovalenko EI; Kadagidze ZG
Bull Exp Biol Med; 2018 Dec; 166(2):241-244. PubMed ID: 30488197
[TBL] [Abstract][Full Text] [Related]
2. Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study.
Cimino-Mathews A; Ye X; Meeker A; Argani P; Emens LA
Hum Pathol; 2013 Oct; 44(10):2055-63. PubMed ID: 23701942
[TBL] [Abstract][Full Text] [Related]
3. Differential regulation and function of tumor-infiltrating T cells in different stages of breast cancer patients.
Zhu S; Lin J; Qiao G; Xu Y; Zou H
Tumour Biol; 2015 Sep; 36(10):7907-13. PubMed ID: 25953262
[TBL] [Abstract][Full Text] [Related]
4. Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast.
Leong PP; Mohammad R; Ibrahim N; Ithnin H; Abdullah M; Davis WC; Seow HF
Immunol Lett; 2006 Feb; 102(2):229-36. PubMed ID: 16246429
[TBL] [Abstract][Full Text] [Related]
5. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
6. Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients--an immunohistochemical study of Cd8+ and Foxp3+ using double immunostaining with correlation to the pathobiological response of the patients.
Chan MS; Wang L; Felizola SJ; Ueno T; Toi M; Loo W; Chow LW; Suzuki T; Sasano H
Int J Biol Markers; 2012 Dec; 27(4):e295-304. PubMed ID: 23280127
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma.
Liyanage UK; Moore TT; Joo HG; Tanaka Y; Herrmann V; Doherty G; Drebin JA; Strasberg SM; Eberlein TJ; Goedegebuure PS; Linehan DC
J Immunol; 2002 Sep; 169(5):2756-61. PubMed ID: 12193750
[TBL] [Abstract][Full Text] [Related]
8. [Lymphocyte activation markers in patients with ovarian cancer].
Nowicka A; Rogala E; Bednarek W; Barczyński B; Wertel I; Piekarczyk W; Kotarski J
Ginekol Pol; 2012 Oct; 83(10):737-43. PubMed ID: 23383558
[TBL] [Abstract][Full Text] [Related]
9. CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast.
Rathore AS; Kumar S; Konwar R; Makker A; Negi MP; Goel MM
Indian J Med Res; 2014 Sep; 140(3):361-9. PubMed ID: 25366203
[TBL] [Abstract][Full Text] [Related]
10. Immunophenotyping of patients with oral squamous cell carcinoma in peripheral blood and associated tumor tissue.
Grimm M; Feyen O; Hofmann H; Teriete P; Biegner T; Munz A; Reinert S
Tumour Biol; 2016 Mar; 37(3):3807-16. PubMed ID: 26474587
[TBL] [Abstract][Full Text] [Related]
11. The composition of T cell infiltrates varies in primary invasive breast cancer of different molecular subtypes as well as according to tumor size and nodal status.
Glajcar A; Szpor J; Hodorowicz-Zaniewska D; Tyrak KE; Okoń K
Virchows Arch; 2019 Jul; 475(1):13-23. PubMed ID: 31016433
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer.
Chin Y; Janseens J; Vandepitte J; Vandenbrande J; Opdebeek L; Raus J
Anticancer Res; 1992; 12(5):1463-6. PubMed ID: 1332579
[TBL] [Abstract][Full Text] [Related]
13. CD8+ T cell infiltration in breast and colon cancer: A histologic and statistical analysis.
Ziai J; Gilbert HN; Foreman O; Eastham-Anderson J; Chu F; Huseni M; Kim JM
PLoS One; 2018; 13(1):e0190158. PubMed ID: 29320521
[TBL] [Abstract][Full Text] [Related]
14. Racial differences in CD8
Abdou Y; Attwood K; Cheng TD; Yao S; Bandera EV; Zirpoli GR; Ondracek RP; Stein L; Bshara W; Khoury T; Ambrosone CB; Omilian AR
Breast Cancer Res; 2020 Jun; 22(1):62. PubMed ID: 32517730
[TBL] [Abstract][Full Text] [Related]
15. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients.
Ali HR; Provenzano E; Dawson SJ; Blows FM; Liu B; Shah M; Earl HM; Poole CJ; Hiller L; Dunn JA; Bowden SJ; Twelves C; Bartlett JM; Mahmoud SM; Rakha E; Ellis IO; Liu S; Gao D; Nielsen TO; Pharoah PD; Caldas C
Ann Oncol; 2014 Aug; 25(8):1536-43. PubMed ID: 24915873
[TBL] [Abstract][Full Text] [Related]
16. Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer.
Mani NL; Schalper KA; Hatzis C; Saglam O; Tavassoli F; Butler M; Chagpar AB; Pusztai L; Rimm DL
Breast Cancer Res; 2016 Jul; 18(1):78. PubMed ID: 27473061
[TBL] [Abstract][Full Text] [Related]
17. IL-15 induces strong but short-lived tumor-infiltrating CD8 T cell responses through the regulation of Tim-3 in breast cancer.
Heon EK; Wulan H; Macdonald LP; Malek AO; Braunstein GH; Eaves CG; Schattner MD; Allen PM; Alexander MO; Hawkins CA; McGovern DW; Freeman RL; Amir EP; Huse JD; Zaltzman JS; Kauff NP; Meyers PG; Gleason MH; Overholtzer MG; Wiseman SS; Streutker CD; Asa SW; McAlindon TP; Newcomb PO; Sorensen PM; Press OA
Biochem Biophys Res Commun; 2015 Aug; 464(1):360-6. PubMed ID: 26141233
[TBL] [Abstract][Full Text] [Related]
18. A morphological and immunophenotypic map of the immune response in Merkel cell carcinoma.
Walsh NM; Fleming KE; Hanly JG; Dakin Hache K; Doucette S; Ferrara G; Cerroni L
Hum Pathol; 2016 Jun; 52():190-6. PubMed ID: 26980039
[TBL] [Abstract][Full Text] [Related]
19. Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study.
Romagnoli G; Wiedermann M; Hübner F; Wenners A; Mathiak M; Röcken C; Maass N; Klapper W; Alkatout I
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885584
[TBL] [Abstract][Full Text] [Related]
20. Tumor-infiltrating CD8+ and FOXP3+ lymphocytes in triple-negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy.
Miyashita M; Sasano H; Tamaki K; Chan M; Hirakawa H; Suzuki A; Tada H; Watanabe G; Nemoto N; Nakagawa S; Ishida T; Ohuchi N
Breast Cancer Res Treat; 2014 Dec; 148(3):525-34. PubMed ID: 25395319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]